Zbigniew Nowecki

9.4k total citations
118 papers, 2.7k citations indexed

About

Zbigniew Nowecki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Zbigniew Nowecki has authored 118 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 24 papers in Cancer Research. Recurrent topics in Zbigniew Nowecki's work include Cancer Treatment and Pharmacology (30 papers), HER2/EGFR in Cancer Research (29 papers) and Advanced Breast Cancer Therapies (24 papers). Zbigniew Nowecki is often cited by papers focused on Cancer Treatment and Pharmacology (30 papers), HER2/EGFR in Cancer Research (29 papers) and Advanced Breast Cancer Therapies (24 papers). Zbigniew Nowecki collaborates with scholars based in Poland, United States and United Kingdom. Zbigniew Nowecki's co-authors include Piotr Rutkowski, W. Ruka, Anna Nasierowska‐Guttmejer, Wanda Michej, Urszula Grzesiakowska, Janusz A. Siedlecki, Wirginiusz Dziewirski, Agnieszka Woźniak, Alexander C. J. van Akkooi and Czesław Osuch and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Zbigniew Nowecki

102 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zbigniew Nowecki Poland	26	1.6k	1.1k	686	512	510	118	2.7k
Christian Meyer zum Büschenfelde Germany	20	1.4k 0.9×	1.1k 1.0×	250 0.4×	730 1.4×	409 0.8×	31	2.4k
Heung-Moon Chang South Korea	25	1.4k 0.9×	908 0.9×	222 0.3×	673 1.3×	349 0.7×	79	2.1k
W. Ruka Poland	25	1.4k 0.9×	1.4k 1.3×	589 0.9×	493 1.0×	440 0.9×	58	2.6k
Neeta Somaiah United States	30	1.4k 0.9×	1.7k 1.7×	329 0.5×	280 0.5×	793 1.6×	169	2.9k
Kumudu Pathiraja United States	17	2.7k 1.7×	1.2k 1.1×	195 0.3×	575 1.1×	489 1.0×	36	3.4k
David R. D’Adamo United States	30	2.6k 1.7×	3.2k 3.1×	516 0.8×	558 1.1×	824 1.6×	65	4.9k
Geneviève Monges France	30	3.0k 1.9×	1.2k 1.1×	382 0.6×	1.5k 2.9×	788 1.5×	77	4.3k
Narasimhan P. Agaram United States	51	2.4k 1.5×	3.8k 3.6×	788 1.1×	1.0k 2.0×	1.2k 2.3×	109	6.4k
Adele Clarkson Australia	38	1.3k 0.8×	1.0k 1.0×	252 0.4×	808 1.6×	947 1.9×	69	3.6k
Sadafumi Tamiya Japan	36	1.2k 0.7×	1.9k 1.8×	261 0.4×	563 1.1×	1.2k 2.3×	143	3.6k

Countries citing papers authored by Zbigniew Nowecki

Since Specialization

Citations

This map shows the geographic impact of Zbigniew Nowecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zbigniew Nowecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zbigniew Nowecki more than expected).

Fields of papers citing papers by Zbigniew Nowecki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zbigniew Nowecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zbigniew Nowecki. The network helps show where Zbigniew Nowecki may publish in the future.

Co-authorship network of co-authors of Zbigniew Nowecki

This figure shows the co-authorship network connecting the top 25 collaborators of Zbigniew Nowecki. A scholar is included among the top collaborators of Zbigniew Nowecki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zbigniew Nowecki. Zbigniew Nowecki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Olszewski, Wojciech, et al.. (2025). Residual Breast Tissue After Four Types of Mastectomy: A Prospective, Comparative Study. Annals of Surgical Oncology. 32(8). 5467–5476.

Fasching, Peter A., Dennis J. Slamon, Zbigniew Nowecki, et al.. (2025). Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. Clinical Cancer Research. 31(9). 1625–1635. 2 indexed citations

Borowiec, Anna, Magdalena Rosińska, Beata Kotowicz, et al.. (2025). Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha. International Journal of Molecular Sciences. 26(9). 4071–4071. 2 indexed citations

Borowiec, Anna, Magdalena Rosińska, Beata Kotowicz, et al.. (2025). Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study. Pharmaceuticals. 18(8). 1102–1102.

Olszewski, Wojciech, et al.. (2025). ASO Visual Abstract: Residual Breast Tissue after Four Types of Mastectomy—A Prospective, Comparative Study. Annals of Surgical Oncology. 32(8). 5583–5584.

Fuksiewicz, Małgorzata, Anna Borowiec, Katarzyna Pogoda, et al.. (2025). Neurofilaments as Prognostic Biomarkers in the Assessment of the Risk of Advanced Taxane-Induced Neuropathy in Breast Cancer Patients—A Pilot Study. Cancers. 17(6). 988–988.

Juric, Dejan, Kevin Kalinsky, Nicholas C. Turner, et al.. (2024). First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.. Journal of Clinical Oncology. 42(16_suppl). 1003–1003. 23 indexed citations

Borowiec, Anna, Magdalena Rosińska, Agnieszka Jagiełło-Gruszfeld, et al.. (2023). Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study. PLoS ONE. 18(8). e0288146–e0288146. 7 indexed citations

Jagiełło-Gruszfeld, Agnieszka, et al.. (2023). Immediate breast reconstruction in breast cancer patients with the use of Serasynth and SeragynBR synthetic meshes. Single-oncological center experience, analysis of complications. Polish Journal of Surgery. 96(2). 11–20.

10.

Fuksiewicz, Małgorzata, et al.. (2023). Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study. Cancers. 15(22). 5446–5446. 2 indexed citations

11.

Pogoda, Katarzyna, et al.. (2023). Recent advances in the treatment of triple-negative breast cancer. Oncology in Clinical Practice. 19(6). 433–443. 1 indexed citations

12.

Jagiełło-Gruszfeld, Agnieszka, et al.. (2022). Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers. 14(5). 1218–1218. 6 indexed citations

13.

Pogoda, Katarzyna, Anna Niwińska, Elżbieta Sarnowska, et al.. (2020). Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis. Journal of Oncology. 2020. 1–10. 34 indexed citations

14.

Mayer, Erica L., Angela DeMichele, Miguel Martín, et al.. (2020). LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Annals of Oncology. 31. S1145–S1145. 23 indexed citations

15.

Turner, Nicholas C., Rebecca Dent, Joyce O’Shaughnessy, et al.. (2020). 283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial. Annals of Oncology. 31. S354–S355. 10 indexed citations

16.

Pivot, Xavier, Igor Bondarenko, Zbigniew Nowecki, et al.. (2017). One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment. Annals of Oncology. 28. v45–v45. 6 indexed citations

17.

Rutkowski, Piotr & Zbigniew Nowecki. (2011). Sarcomas and melanomas. Postępy Nauk Medycznych. 1 indexed citations

18.

Kulik, Anna, Tadeusz Morysiński, Zbigniew Nowecki, et al.. (2010). Surgery combined with brachytherapy in patients with retroperitoneal sarcomas. SHILAP Revista de lepidopterología. 1 indexed citations

19.

Ruka, W., Piotr Rutkowski, Maciej Krzakowski, et al.. (2009). Soft tissue sarcoma - diagnosis and treatment. Oncology in Clinical Practice. 5(5). 198–210. 6 indexed citations

20.

Dêbiec‐Rychter, Maria, Piotr Rutkowski, Peter Reichardt, et al.. (2007). Aktualne postępowanie diagnostyczno-terapeutyczne u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST). Nowotwory Journal of Oncology. 57(2). 181–181. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact